Figure 4.

Pramlintide reduces diurnal glucose fluctuations. Patients with type 1 or type 2 diabetes in an open-label study self-monitored blood glucose for a 7 point glucose profile at baseline and following 6-months of pramlintide treatment. Readings were recorded before and after the 3 major meals of the day and before bedtime. (A) In patients with type 2 diabetes (n=166), pramlintide 120 μg three times daily (TID) and twice daily (BID) significantly reduced blood glucose concentrations following all three major meals (*indicates p<0.05). (B) In patients with type 1 diabetes (n=265), pramlintide 30–60 μg TID and four times daily (QID) significantly reduced blood glucose concentrations following breakfast and lunch (*indicates p<0.05) (Guthrie et al 2005; Karl et al 2005).

Abbreviations: SE, standard error of mean.